Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,614 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04540757 | Impact on Quality of Life From Multi-modality Lung Cancer(PIONEER) | unknown | — | 66 | The Christie NHS Foundation TrustOTHER | 1 | Feb 3, 2022 | clinicaltrials |
| NCT05221814 | Pathological Classification of Pulmonary Nodules in Images Using Deep Learning | unknown | — | 2,000 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Feb 3, 2022 |
| clinicaltrials |
| NCT05180851 | Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study(YSCH-01) | unknown | Early Phase 1 | 28 | Shanghai Fengxian District Central HospitalOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT05218759 | Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC | unknown | N/A | 30 | Shanghai Chest HospitalOTHER | 0 | Feb 1, 2022 | clinicaltrials |
| NCT05210946 | A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients | unknown | N/A | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT05207904 | Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases | unknown | Phase 2 | 41 | Sun Yat-sen UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05209256 | Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC | unknown | Phase 2 / Phase 3 | 90 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 0 | Jan 26, 2022 | clinicaltrials |
| NCT05204628 | A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib | unknown | Phase 3 | 238 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 24, 2022 | clinicaltrials |
| NCT01024829 | Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using FDG-PET-CT Scan in Stage IB, II and III NSCLC(PET Boost) | unknown | N/A | 150 | The Netherlands Cancer InstituteOTHER | 5 | Jan 21, 2022 | clinicaltrials |
| NCT04595734 | Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors. | unknown | — | 500 | Western Sydney Local Health DistrictOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT05065398 | A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation | unknown | Phase 2 | 20 | Shanghai Henlius BiotechINDUSTRY | 1 | Jan 21, 2022 | clinicaltrials |
| NCT05165355 | Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma(ATHEM) | unknown | Phase 2 | 90 | Tongji UniversityOTHER | 1 | Jan 18, 2022 | clinicaltrials |
| NCT05191849 | Circulating EV Long RNA Profiles in SCLC | unknown | N/A | 60 | Fudan UniversityOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT05192681 | Tislelizumab as Cross-line Treatment for Advanced NSCLC | unknown | Phase 2 | 35 | Fujian Cancer HospitalOTHER_GOV | 1 | Jan 14, 2022 | clinicaltrials |
| NCT05158491 | Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC | unknown | Phase 1 / Phase 2 | 63 | JenKem Technology Co., Ltd.INDUSTRY | 1 | Jan 5, 2022 | clinicaltrials |
| NCT05176067 | Randomized Controlled Clinical Study of Drug Therapy Combined With Thoracic Radiotherapy for Non-oligometastatic NSCLC | unknown | N/A | 88 | Guizhou Medical UniversityOTHER | 0 | Jan 4, 2022 | clinicaltrials |
| NCT05177497 | SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC | unknown | Phase 2 | 19 | Shanghai Chest HospitalOTHER | 0 | Jan 4, 2022 | clinicaltrials |
| NCT04529915 | Multicenter Clinical Research for Early Diagnosis of Lung Cancer Using Blood Plasma Derived Exosome | unknown | — | 470 | Korea University Guro HospitalOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT04025424 | Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519)(ICIPRESIST19) | unknown | — | 350 | Russian Academy of Medical SciencesOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05170581 | Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung Cancer | unknown | Phase 2 | 30 | The Second Affiliated Hospital of Shandong First Medical UniversityOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05167604 | Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC | unknown | — | 150 | Tang-Du HospitalOTHER | 1 | Dec 22, 2021 | clinicaltrials |
| NCT05167851 | The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer | unknown | Phase 2 | 68 | Yonsei UniversityOTHER | 1 | Dec 22, 2021 | clinicaltrials |
| NCT02743923 | Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer | unknown | Phase 3 | 203 | The Netherlands Cancer InstituteOTHER | 1 | Dec 21, 2021 | clinicaltrials |
| NCT05162235 | Augmented Reality-assisted Localization of Solitary Pulmonary Nodules for Precise Sublobar Lung Resection(ARPL) | unknown | N/A | 20 | Shanghai Chest HospitalOTHER | 0 | Dec 17, 2021 | clinicaltrials |
| NCT05157503 | Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia" | unknown | — | 1 | Autonomous Non-Profit Organization National Society of Onco-PulmonologistsOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT05157542 | Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC | unknown | Phase 1 | 9 | Juan LI, MDOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT04901754 | Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer(CAMERA) | unknown | Phase 2 | 38 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 8, 2021 | clinicaltrials |
| NCT04989322 | Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC | unknown | Phase 2 | 46 | Dr Joanne CHIUOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT05072561 | Feasibility of Radioisotope-guided Excision of Mediastinal Lymph Nodes in Patients With Non-small Cells Lung Carcinoma(SLN_NSCLC) | unknown | N/A | 60 | Istituto Clinico HumanitasOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT05141786 | A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC). | unknown | Phase 2 | 100 | Shanghai Miracogen Inc.INDUSTRY | 1 | Dec 2, 2021 | clinicaltrials |
| NCT02897479 | A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer | unknown | Phase 2 | 76 | Hutchison Medipharma LimitedINDUSTRY | 1 | Nov 30, 2021 | clinicaltrials |
| NCT05134558 | Xenon-enhanced Ventilation CT-guided Radiotherapy for Lung Cancer Treatment | unknown | N/A | 60 | National Taiwan University HospitalOTHER | 1 | Nov 26, 2021 | clinicaltrials |
| NCT05136014 | Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model(OS-TUMOVASC) | unknown | — | 200 | Central Hospital, Nancy, FranceOTHER | 1 | Nov 26, 2021 | clinicaltrials |
| NCT05132218 | Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer(EFLRWR) | unknown | — | 180 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT05132777 | Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer | unknown | Phase 2 | 155 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Nov 24, 2021 | clinicaltrials |
| NCT04405674 | Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC | unknown | Phase 2 | 120 | Shanghai Chest HospitalOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT02824952 | Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC | unknown | Phase 2 | 40 | Shaare Zedek Medical CenterOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT04000620 | Imaging-based Deep Learning for Lung Cancer Diagnosis and Staging | unknown | — | 500 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT05046366 | Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology. | unknown | — | 1,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT05121233 | Local Anesthesia Versus Combined Local Anesthesia With Single Dose Analgesia on Pain Control During Thoracic Ultrasound Guided Procedures | unknown | Phase 4 | 100 | Assiut UniversityOTHER | 0 | Nov 16, 2021 | clinicaltrials |
| NCT05120050 | Clinical Evaluation of ASP Health's Automated ROSE System for Bronchoscopic Applications | unknown | — | 100 | ASP HealthINDUSTRY | 0 | Nov 15, 2021 | clinicaltrials |
| NCT05117138 | Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors | unknown | Phase 1 / Phase 2 | 39 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Nov 11, 2021 | clinicaltrials |
| NCT05117372 | ANALYSIS OF INFLAMMATORY REACTIONS OBSERVED IN BRONCHOALVEOLAR LAVAGES (BALS)(LBA-PI) | unknown | N/A | 34 | Centre Chirurgical Marie LannelongueOTHER | 1 | Nov 11, 2021 | clinicaltrials |
| NCT04984148 | Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC | unknown | — | 70 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 9, 2021 | clinicaltrials |
| NCT05073991 | Incidence of Mortality and Complications After Lung Surgery, Open Thoracic Aortic Repair, TEVAR, EVAR. | unknown | — | 2,224 | Mahidol UniversityOTHER | 1 | Nov 1, 2021 | clinicaltrials |
| NCT05098990 | Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC | unknown | Phase 4 | 328 | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.INDUSTRY | 0 | Oct 29, 2021 | clinicaltrials |
| NCT05097417 | Traditional Chinese Medicine Combined With Thermal and Cold Ablation for Early-stage Lung Cancer | unknown | N/A | 110 | Shanghai 10th People's HospitalOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT05094167 | Lactobacillus Bifidobacterium V9(Kex02)Improving the Efficacy of Carilizumab Combined With Platinum in Non-small Cell Lung Cancer Patients | unknown | N/A | 46 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT04056273 | Assess the Use of rEBUS With a Guide Sheath to Increase Transbronchial Lung Biopsy Yield Rate | unknown | N/A | 586 | National Taiwan University HospitalOTHER | 1 | Oct 20, 2021 | clinicaltrials |
| NCT05079022 | ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas | unknown | Phase 1 / Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Oct 15, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Feb 3, 2022source: clinicaltrials